Calls
2
u/fbksminer
Reddit r/biotech_stocks
Win Rate
0.0%
return
-28.3%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 18
$20.52
-13.6%
The author estimates from the Q3 10-Q and preliminary Q4 figures that Syndax revenues are expanding at a phenomenal rate, with Q4 EPS of about -$0.53 versus -$0.83 in Q2 and -$0.70 in Q3. Revuforj revenue rose 38% quarter-over-quarter and Niktimvo also increased, with the author projecting break-even or profitability by Q3. Catalysts include two Phase III trials (one global), an MD Anderson independent trial expanding Revuforj use, and Incyte's Phase II expansion of Niktimvo. The author cautions these are personal napkin estimates and readers must do their own due diligence.
Pharma & Biotech
Long
Jan 01
$14.40
-43.0%
Author expects REGENXBIO shares to rise 50% by end of year. The Hunter syndrome PDUFA date is February 8, and the FDA delay was due to new longer-term data that the author says results were great. Approval would include a priority review voucher, which the author notes last sold for $160 million. Additionally, pivotal DMD results are expected in Q1 with a filing in mid-2026.
Pharma & Biotech
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/fbksminer has 2 trade ideas tracked on Buzzberg across 2 tickers since January 2026. Most covered: RGNX, SNDX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
